Our key technologies improve on existing approaches to liquid biopsy for several advantages in cancer detection.  NexGenAbler™ (NGA) is a more specific, sensitive, and automation-friendly method for quantitative measurement of mutations in cell-free DNA (cfDNA). PointSuppressor™ works seamlessly with NGA to suppress unwanted wild type reads, lowering the limit of detection and decreasing sequencing costs by orders of magnitude. MethylMarker™ enables measurement of methylation and mutation detection in the same tube. Each method substantially enhances liquid biopsy. Combined, these technologies will dramatically improve detection and monitoring of cancer.